CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jan 3

PMID 34975832

Citations 12

Authors

Mette Scheller Nissen

Matias Ryding

Anna Christine Nilsson

Jonna Skov Madsen

Dorte Aalund Olsen

Ulrich Halekoh

Magnus Lydolph

Zsolt Illes

Morten Blaabjerg

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: The two most common autoimmune encephalitides (AE), -methyl-D-Aspartate receptor (NMDAR) and Leucine-rich Glioma-Inactivated 1 (LGI1) encephalitis, have been known for more than a decade. Nevertheless, no well-established biomarkers to guide treatment or estimate prognosis exist. Neurofilament light chain (NfL) has become an unspecific screening marker of axonal damage in CNS diseases, and has proven useful as a diagnostic and disease activity marker in neuroinflammatory diseases. Only limited reports on NfL in AE exist. We investigated NfL levels at diagnosis and follow-up in NMDAR and LGI1-AE patients, and evaluated the utility of CSF-NfL as a biomarker in AE.

Methods: Patients were included from the National Danish AE cohort (2009-present) and diagnosed based upon autoantibody positivity and diagnostic consensus criteria. CSF-NfL was analyzed by single molecule array technology. Clinical and diagnostic information was retrospectively evaluated and related to NfL levels at baseline and follow-up. NMDAR-AE patients were subdivided into: idiopathic/teratoma associated or secondary NMDAR-AE (post-viral or concomitant with malignancies/demyelinating disease).

Results: A total of 74 CSF samples from 53 AE patients (37 NMDAR and 16 LGI1 positive) were included in the study. Longitudinal CSF-NfL levels was measured in 21 patients. Median follow-up time was 23.8 and 43.9 months for NMDAR and LGI1-AE respectively. Major findings of this study are: i) CSF-NfL levels were higher in LGI1-AE than in idiopathic/teratoma associated NMDAR-AE at diagnosis; ii) CSF-NfL levels in NMDAR-AE patients distinguished idiopathic/teratoma cases from cases with other underlying etiologies (post-viral or malignancies/demyelinating diseases) and iii) Elevated CSF-NfL at diagnosis seems to be associated with worse long-term disease outcomes in both NMDAR and LGI1-AE.

Discussion: CSF-NfL measurement may be beneficial as a prognostic biomarker in NMDAR and LGI1-AE, and high CSF-NfL could foster search for underlying etiologies in NMDAR-AE. Further studies on larger cohorts, using standardized methods, are warranted.

Citing Articles

Neurofilament light chain levels in neuronal surface antibody-associated autoimmune encephalitis: a systematic review and meta-analysis.

Lai Q, Cai M, Li E, Fang G, Shen C, Xu Y Transl Psychiatry. 2025; 15(1):25.

PMID: 39856041 PMC: 11760525. DOI: 10.1038/s41398-025-03241-6.

Emerging Biomarkers for the Early Detection of Autoimmune Encephalitis: A Narrative Review.

Bokhari S, Almadhoun M, Khan M, Ahmad S, Awan M, Imran M Cureus. 2024; 16(9):e69038.

PMID: 39391424 PMC: 11464805. DOI: 10.7759/cureus.69038.

MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis: A Systematic Review and Meta-analysis.

Almeida F, Pereira A, Mendes-Pinto C, Lopes J, Moura J, Sousa J AJNR Am J Neuroradiol. 2024; 45(7):977-986.

PMID: 38871367 PMC: 11286010. DOI: 10.3174/ajnr.A8256.

Cerebral clues: serum neurofilament light chain (sNfL) as a novel biomarker for immune check point inhibitor (ICI) mediated seronegative encephalitis.

Zahid A, Tummala S Oxf Med Case Reports. 2024; 2024(6):omae058.

PMID: 38860018 PMC: 11162591. DOI: 10.1093/omcr/omae058.

Neurofilaments as biomarkers in neurological disorders - towards clinical application.

Khalil M, Teunissen C, Lehmann S, Otto M, Piehl F, Ziemssen T Nat Rev Neurol. 2024; 20(5):269-287.

PMID: 38609644 DOI: 10.1038/s41582-024-00955-x.

References

Vagberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H . Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015; 10(8):e0135886. PMC: 4552591. DOI: 10.1371/journal.pone.0135886. View

Ulusoy C, Tuzun E, Kurtuncu M, Turkoglu R, Akman-Demir G, Eraksoy M . Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders. Int J Neurosci. 2011; 122(6):284-9. DOI: 10.3109/00207454.2011.648762. View

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-61. DOI: 10.1515/cclm-2015-1195. View

Heine J, Kopp U, Klag J, Ploner C, Pruss H, Finke C . Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol. 2021; 90(6):949-961. DOI: 10.1002/ana.26241. View

Levraut M, Bourg V, Capet N, Delourme A, Honnorat J, Thomas P . Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. Front Immunol. 2021; 12:673021. PMC: 8158812. DOI: 10.3389/fimmu.2021.673021. View

Sejbaek T, Mendoza J, Penner N, Madsen J, Olsen D, Illes Z . Comparison of neurofilament light chain results between two independent facilities. BMJ Neurol Open. 2021; 2(2):e000063. PMC: 7871722. DOI: 10.1136/bmjno-2020-000063. View

Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4):391-404. PMC: 5066574. DOI: 10.1016/S1474-4422(15)00401-9. View

Irani S, Alexander S, Waters P, Kleopa K, Pettingill P, Zuliani L . Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010; 133(9):2734-48. PMC: 2929337. DOI: 10.1093/brain/awq213. View

Irani S, Vincent A . The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr. 2012; 70(4):300-4. DOI: 10.1590/s0004-282x2012000400015. View

10.

Dalmau J, Graus F . Antibody-Mediated Encephalitis. N Engl J Med. 2018; 378(9):840-851. DOI: 10.1056/NEJMra1708712. View

11.

Titulaer M, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T . Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2):157-65. PMC: 3563251. DOI: 10.1016/S1474-4422(12)70310-1. View

12.

Makuch M, Wilson R, Al-Diwani A, Varley J, Kienzler A, Taylor J . N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications. Ann Neurol. 2018; 83(3):553-561. PMC: 5925521. DOI: 10.1002/ana.25173. View

13.

Tuzun E, Zhou L, Baehring J, Bannykh S, Rosenfeld M, Dalmau J . Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009; 118(6):737-43. PMC: 2888642. DOI: 10.1007/s00401-009-0582-4. View

14.

Guasp M, Modena Y, Armangue T, Dalmau J, Graus F . Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020; 7(2). PMC: 6975174. DOI: 10.1212/NXI.0000000000000659. View

15.

Byun J, Lee S, Moon J, Jung K, Sunwoo J, Lim J . Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. J Neuroimmunol. 2016; 297:141-7. DOI: 10.1016/j.jneuroim.2016.05.023. View

16.

Modvig S, Degn M, Roed H, Sorensen T, Larsson H, Langkilde A . Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015; 21(14):1761-70. DOI: 10.1177/1352458515574148. View

17.

Mariotto S, Gajofatto A, Zuliani L, Zoccarato M, Gastaldi M, Franciotta D . Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. J Neurol. 2019; 266(7):1643-1648. DOI: 10.1007/s00415-019-09306-z. View

18.

Wilke C, Pujol-Calderon F, Barro C, Stransky E, Blennow K, Michalak Z . Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clin Chem Lab Med. 2019; 57(10):1556-1564. DOI: 10.1515/cclm-2019-0015. View

19.

Nass R, Akgun K, Elger C, Reichmann H, Wagner M, Surges R . Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. Seizure. 2020; 85:1-5. DOI: 10.1016/j.seizure.2020.12.009. View

20.

Martinez-Hernandez E, Guasp M, Garcia-Serra A, Maudes E, Arino H, Sepulveda M . Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology. 2020; 94(22):e2302-e2310. DOI: 10.1212/WNL.0000000000009239. View